KROS
Keros Therapeutics, Inc.
Biotechnology · Healthcare · United States
10.66
close · 2026-08-13
value
87
cheaper than peers87
quality
26
stronger fundamentals26
ranked against
Biotechnology (commercial)
value
quality
101 peerswide variation
Value inputs
| measure | company | vs peers |
| price to book | 0.74× | 98 |
| EV to EBITDA | 0.32× | 93 |
| price to sales | 14.72× | 45 |
3 of 12 measures available
Quality inputs
| measure | company | vs peers |
| debt to equity | 6.0% | 73 |
| return on equity | -17.2% | 64 |
| operating margin | -655.8% | 20 |
| revenue growth | -99.8% | 1 |
4 of 4 measures available
Facts
| market cap | $211M |
| free cash flow | -$27.2M |
| employees | 92 |
| first trade | 2020-04-08 |
| next earnings | 2026-08-03 |
| fundamentals updated | 2026-08-07 |